AR and prostate cancer: In the human androgen-dependent prostate cancer cells LNCaP and LAPC4, AR activation with the synthetic androgen R1881 increases the HKII, PFK-platelet isoform, ENO, and PGK mRNA contents versus nontreated cells (Figure 1, Table 2), as well as the glycolytic rate, which is measured as the extracellular acidification rate (Table 2).